Merck and Eisai showed their Keytruda-Lenvima combo could cut the risk of death by 34% over Pfizer’s old standard treatment Sutent in newly diagnosed kidney cancer. While the overall survival showing was very similar to the numbers for three other immuno-oncology cocktails based on Keytruda or Bristol Myers Squibb’s Opdivo, SVB Leerink analyst Daina Graybosch pointed to other efficacy data in crowning the Keytruda-Lenvima pairing as the “clear choice.” But the win is not a done deal at this point, she noted.
AbbVie’s Allergan and its South Korean partner MedyTox have decided to settle the legal battle they waged against Evolus and its own Korean partner Daewoong Pharmaceutical over their wrinkle-lifting drugs. The news came on the heels of a U.S. appeals court s decision to temporarily allow the Evolus pair’s Botox rival, Jeuveau, to stay on the U.S. market as it reviewed an import ban installed by the U.S. International Trade Commission. AbbVie and Medytox abandoned
Global Tumor Ablation Market Is Expected to Reach USD 1,634 Million by 2028 : Fior Markets
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Tumor Ablation Market 2021 Global Trends, Top players, Demand, Share, Segmentation and Forecast to 2026
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Glenmark
Glenmark launches SUTIB (Sunitinib) - priced 96% lower than the innovator brand- Reduces the risk of kidney cancer progression by 58% ANI | Updated: Feb 16, 2021 12:24 IST
Mumbai (Maharashtra) [India], February 16 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India.
The drug is launched at a MRP that is approx. 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).
Kidney cancer (renal cell carcinoma) is a disease of uncontrolled cell growth in the lining of small tubes in the kidney. In the past decade, advances in research and drug development have begun to shift the paradigm of this disease.
Trending
A case study was published in the Journal of Medical Case Reports of a man suffering with a varicocele.
The 54-year-old man had a left-sided varicocele and was also suffering with lower abdominal pain and a decrease in urination.
Four months previously, he had noticed pain and swelling in his left groin and had been diagnosed with left-sided varicocele.
His blood tests revealed severe kidney injury.
“Varicoceles could be an early presentation of a non-functioning adrenocortical carcinoma,” said the study.
It added: “Acute kidney injury can occur as a result of mass effect or thrombosis of renal vessels.
“Large tumours can cause abdominal pain as a late manifestation.